Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticlePractice

Effectiveness of omalizumab in severe persistent asthma under real-life conditions

Anthony D. D’Urzo and Jenny Wong
Canadian Family Physician July 2014; 60 (7) 643-645;
Anthony D. D’Urzo
Associate Professor in the Department of Family and Community Medicine at the University of Toronto in Ontario.
MD MSc CCFP FCFP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jenny Wong
Family medicine resident at McGill University in Montreal, Que.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

Jump to comment:

  • Omalizumab critical appraisal
    Mike E Cotterill
    Published on: 01 August 2014
  • Published on: (1 August 2014)
    Page navigation anchor for Omalizumab critical appraisal
    Omalizumab critical appraisal
    • Mike E Cotterill, family physician

    To the editor: I read with interest the critical appraisal on Omalizumab. I thought there were a few questions that readers might have in order to "critically appraise" this Critical Appraisal: 1. Dr. D'Urzo lists that he has received fees from Novartis, one of the manufacturers of omalizumab. Did he receive fees specifically related to omalizumab? Were the Belgian physicians in the study paid to participate? 2. What kin...

    Show More

    To the editor: I read with interest the critical appraisal on Omalizumab. I thought there were a few questions that readers might have in order to "critically appraise" this Critical Appraisal: 1. Dr. D'Urzo lists that he has received fees from Novartis, one of the manufacturers of omalizumab. Did he receive fees specifically related to omalizumab? Were the Belgian physicians in the study paid to participate? 2. What kind of literature search was done to obtain this article? 3. Was the PERSIST study funded by the manufacturer of omalizumab? 4. Were the endpoints specified and published prior to the conduct of the trial? 5. Why select a non-randomized, uncontrolled, unblinded study? Wouldn't this be susceptible to placebo effect? Could the result be due only to the natural progression of the disease? 6. Are the various questionnaires and criteria used externally validated? 7. Given Canadian family physicians probable unfamiliarity with omalizumab, and its high cost (>$600 / 150 mg treatment), is it better than existing treatments? Sincerely, Mike Cotterill

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
PreviousNext
Back to top

In this issue

Canadian Family Physician: 60 (7)
Canadian Family Physician
Vol. 60, Issue 7
1 Jul 2014
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effectiveness of omalizumab in severe persistent asthma under real-life conditions
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effectiveness of omalizumab in severe persistent asthma under real-life conditions
Anthony D. D’Urzo, Jenny Wong
Canadian Family Physician Jul 2014, 60 (7) 643-645;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Effectiveness of omalizumab in severe persistent asthma under real-life conditions
Anthony D. D’Urzo, Jenny Wong
Canadian Family Physician Jul 2014, 60 (7) 643-645;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Clinical question
    • Type of article and design
    • Relevance to family medicine
    • Overview of study outcomes
    • Results
    • Analysis of methodology
    • Application to clinical practice
    • Notes
    • Footnotes
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Approach to diagnosis and management of childhood attention deficit hyperactivity disorder
  • Determining if and how older patients can safely stay at home with additional services
  • Managing type 2 diabetes in primary care during COVID-19
Show more Practice

Critical Appraisal

  • New therapy for managing moderate to severe chronic obstructive pulmonary disease
  • Four-year trial of tiotropium in chronic obstructive pulmonary disease
Show more Critical Appraisal

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire